Exegenesis Bio is a rapidly growing global gene therapy company that is reimagining the ways to treat genetic diseases and in ... crease patient access to critical genetic medicines. Founded in 2019 with strong financial backing, Exegenesis Bio has developed a rich pipeline of early to clinical stage programs in eye, CNS and liver-directed genetic diseases. The company is building fully integrated, research, development and manufacturing capabilities to support its programs at commercial scale. Exegenesis Bio has recruited a globally experienced management team with extensive experience in building and scaling biotechnology and gene therapy companies. The company has raised over $120 M since beginning operations in 2019 and is now expanding operations to Philadelphia, Boston and Singapore. Exegenesis Bio expects to dose the first patient with its next generation AAV gene therapy for Type 1 Spinal Muscular Atrophy (SMA) this year. The company plans to file two Global INDs in 2022. Website: https://www.exegenesisbio.com/ Contacts: Company Information: Contact@ExegenesisBio.com Business Development: BD@ExegenesisBio.com Careers: Careers@ExegenesisBio.com read more